Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis ; PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF.
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF.
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS)
Passage Bio, Inc. (NASDAQ:PASG – Get Free Report) saw a large decrease in short interest during the month of June. As of June 30th, there was short interest totalling 221,100 shares, a decrease of 26.4% from the June 15th total of 300,400 shares. Currently, 0.7% of the company’s stock are short sold. Based on an […]